Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Zenas BioPharma, Inc. due to allegations of violations of federal securities laws, specifically regarding misleading statements about the company's financial status and operational funding [2][4]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Zenas to contact them for discussing legal options [1]. - A federal securities class action has been filed against Zenas, with a deadline of June 16, 2025, for investors to seek the role of lead plaintiff [2][4]. - The complaint alleges that Zenas materially overstated its ability to fund operations with existing cash and expected IPO proceeds, leading to misleading public statements [4]. Group 2: Class Action Details - The lead plaintiff in a class action is the investor with the largest financial interest who directs the litigation on behalf of the class [5]. - Any member of the class can move to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [5]. Group 3: Additional Information - Faruqi & Faruqi encourages anyone with information regarding Zenas' conduct, including whistleblowers and former employees, to contact the firm [6]. - For more information about the class action, interested parties can visit the firm's website or contact the partner directly [7].

Core Viewpoint - Retail investors in Zenas BioPharma, Inc. may have the opportunity to lead a securities class action lawsuit due to alleged misrepresentation of the company's financial position during its IPO [1][4]. Group 1: Lawsuit Details - The lawsuit is filed in the U.S. District Court for the District of Massachusetts, accusing Zenas BioPharma of misrepresenting its financial status in IPO registration materials [4]. - Zenas BioPharma claimed it had sufficient funds to operate for 24 months, but later disclosed a funding runway of only 12 months in its third-quarter financials [4]. - Since the IPO, Zenas BioPharma's stock price has decreased by nearly 49%, dropping from $17 to $8.72 as of April 15, 2025 [4]. Group 2: Lead Plaintiff Information - A lead plaintiff plays an active role in the litigation and represents the interests of all class members, typically being the investor or group with the largest financial interest [5]. - Filing a motion to be appointed as lead plaintiff is not necessary to share in any recovery, but it allows for a voice in the litigation process [6]. Group 3: Law Firm Background - Cohen Milstein is recognized as a leading plaintiff-side law firm specializing in securities litigation and investor protection, having recovered billions for shareholders [7]. - The firm has received accolades from industry publications, ranking its work and attorneys among the best in the nation [7].

Core Points - A class action lawsuit has been filed against Zenas BioPharma, Inc. for alleged securities fraud and unlawful business practices [2][4] - Investors who purchased Zenas securities during its initial public offering (IPO) are encouraged to join the class action by contacting Pomerantz LLP [1][2] - Zenas conducted its IPO on September 13, 2024, selling approximately 13.235 million shares at $17.00 per share, but its stock price has significantly declined since then [4] Company Information - Zenas BioPharma, Inc. is facing legal scrutiny due to claims of misleading statements regarding its financial stability post-IPO [2][4] - The company stated it could fund operations for "at least" the next twelve months, contrary to earlier claims of twenty-four months in its IPO registration [4] Legal Context - The deadline for investors to request appointment as Lead Plaintiff in the class action is June 16, 2025 [2] - Pomerantz LLP is recognized for its expertise in corporate and securities class litigation, having a long history of advocating for victims of securities fraud [5]

NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Zenas BioPharma, Inc. (NASDAQ: ZBIO) pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with Zenas BioPharma’s September 2024 initial public offering (“IPO” or the “Offering”), of the important June 16, 2025 lead plaintiff deadline in the securities class action first filed by the fi ...

Core Viewpoint - A class action securities lawsuit has been filed against Zenas BioPharma, Inc. due to alleged securities fraud affecting investors who purchased shares during the company's September 2024 initial public offering [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors adversely affected by alleged securities fraud related to Zenas BioPharma's IPO [2]. - The complaint alleges that Zenas BioPharma materially overstated its ability to fund operations using existing cash and expected net proceeds from the IPO, leading to false and misleading public statements [3]. Group 2: Investor Information - Investors who suffered losses in Zenas BioPharma during the relevant time frame have until June 16, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a strong track record in securing compensation for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [5].

WASHINGTON, April 24, 2025 (GLOBE NEWSWIRE) -- Investors in Zenas BioPharma, Inc. (NASDAQ: ZBIO) who bought shares in the company’s September 2024 IPO may be eligible to participate in and lead a class action lawsuit now pending in federal court. Cohen Milstein Sellers & Toll PLLC, a nationally recognized investor rights law firm, is actively investigating claims and encouraging shareholders with significant losses to reach out now. [Click here for information about joining the class action] If you’d like t ...

SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed on behalf of persons who purchased or otherwise acquired Zenas BioPharma, Inc. (NASDAQ: ZBIO) (“Zenas” or the “Company”) securities pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with Zenas’ initial public offering held on September 13, 2024 (the “IPO”), charging the Company, certain senior executives and directors, and the underwriters ...

NEW YORK, April 24, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Zenas BioPharma, Inc. ("Zenas BioPharma, Inc." or the "Company") (NASDAQ: ZBIO) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Zenas BioPharma, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of persons who purchased or otherwise acquired Zenas BioPharma securities pursuant and/or traceable to the registration sta ...

SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Zenas BioPharma, Inc. (NASDAQ: ZBIO) securities pursuant and/or traceable to Zenas BioPharma’s registration statement issued in connection with Zenas BioPharma’s initial public offering (the “IPO”) held on or around September 13, 2024, and were damaged thereby, have until June 16, 2025 to seek appointment as lead plaintiff of the Zenas BioPharma class action lawsuit. Capti ...

NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Zenas BioPharma, Inc. (NASDAQ: ZBIO). Shareholders who purchased shares of ZBIO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/zenas-biopharma-inc-loss-submission-form/?id=144444&from=3  CLASS PERIOD: T ...